Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has shared an announcement.
Qyuns Therapeutics Co., Ltd. has announced that its Phase III clinical trial for QX002N, an injection aimed at treating ankylosing spondylitis, has successfully met its primary endpoint. The trial demonstrated the drug’s superior efficacy and comparable safety to existing treatments, marking a significant milestone in its development. This success positions the company favorably within the market for biologics targeting autoimmune diseases, potentially benefiting stakeholders with new treatment options for patients with moderate-to-severe ankylosing spondylitis.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a biotechnology company based in China, primarily focused on developing innovative biologic treatments. The company’s main product, QX002N, is a monoclonal antibody targeting IL-17A, designed to treat autoimmune diseases like ankylosing spondylitis.
YTD Price Performance: -5.15%
Average Trading Volume: 45,760
Technical Sentiment Consensus Rating: Strong Buy
For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.